The present invention provides methods for treating fragile X syndrome and/or other neurodevelopmental disorders by administering p21 -activated kinase (PAK) modulators to a patient suffering from, susceptible to, and/or exhibiting one or more symptoms of FXS and/or other neurodevelopmental disorders. The present invention provides PAK modulators and pharmaceutical compositions comprising PAK modulators. The present invention further provides methods for identifying and/or characterizing PAK modulators.
申请公布号
WO2008063933(A3)
申请公布日期
2009.03.19
申请号
WO2007US84325
申请日期
2007.11.09
申请人
MASSACHUSETTS INSTITUTE OF TECHNOLOGY;TONEGAWA, SUSUMU;HAYASHI, MANSUO;DOLAN, BRIDGET
